Related Experiment Video
Updated: Feb 13, 2026

Macrophage Differentiation and Polarization into an M2-Like Phenotype using a Human Monocyte-Like THP-1 Leukemia Cell Line
Published on: August 2, 2021
KRTCAP2 accelerates malignant progression through modulating tumor cell function and M2 macrophage infiltration in
Chunmei Zhao1, Yijie Sheng2,3, Jianfei Huang4
1Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
Background:
Aberrant glycosylation of proteins plays a critical role in promoting tumor growth and modulating immune responses within the tumor microenvironment. Keratinocyte-associated protein 2 (KRTCAP2) encodes a corresponding protein involved in N-glycosylation, yet its functional and clinical relevance in glioma remains poorly understood. This study aims to elucidate the dual functions of KRTCAP2 in glioma tumorigenesis and immune evasion, and to evaluate its potential as a prognostic biomarker.
Methods:
We employed bioinformatics analysis to evaluate KRTCAP2 mRNA expression patterns and immune microenvironment scores in glioma. Multiplex immunohistochemistry (mlHC) was utilized to assess KRTCAP2 protein expression, its association with clinical features, patient prognosis, and immune cell infiltration. To assess the function of KRTCAP2 in regulating glioma cell behaviors and its influence on the tumor immune microenvironment, a set of in vitro functional assay were conducted. Additionally, the relationship between KRTCAP2 expression and therapeutic response was examined using the CelIMiner Cross-Database and apoptosis assays.
Results:
KRTCAP2 mRNA and protein levels were markedly upregulated in glioma tissues compared to non-tumorous brain tissues. Elevated KRTCAP2 protein expression correlated with adverse clinical characteristics and reduced overall survival. Notably, KRTCAP2 expression showed a significant positive association with the density of infiltrating CD68+ and CD163+ tumor-associated macrophages (TAMs). Depletion of KRTCAP2 significantly inhibited the proliferative, migratory, and invasive capacities of glioma cells, confirming its role as an oncogenic driver. Conversely, KRTCAP2 overexpression promoted these malignant behaviors. Drug sensitivity analysis suggested a role for KRTCAP2 in chemoresistance, with targeted inhibition enhancing glioma cell responsiveness to temozolomide (TMZ).
Conclusions:
Our findings identify KRTCAP2 as a novel prognostic biomarker in glioma, with potential utility in predicting immunotherapy response. The study highlights its clinical significance and multifaceted role in shaping an immunosuppressive glioma microenvironment, underscoring KRTCAP2 as a promising therapeutic target.
More Related Videos
Related Concept Videos
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Accelerators
The effectiveness of calcium chloride can...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Average Acceleration
Instantaneous Acceleration
Acceleration Vectors

